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THE CHALLENGES OF PRECISION CANCER MEDICINE
In a relatively short space of time, daily practice in oncology
has changed almost beyond recognition. Only 20 years ago,
it would have been difficult to imagine the scale and pace
of the progress that has been achieved. Increasingly specific
diagnostics and unprecedented acceleration in the develop-
ment of innovative new therapies have opened up a myriad
of new treatment options [1]. At the same time, there is
growing evidence that cancer is a generic term for thou-
sands of distinct and rare diseases [2], with exemplars like
breast cancer, for which 11 genetically distinct disease types
have been identified [3]. Collectively, these insights and
innovations are driving the need for a highly personalized
approach to treatment, which is transforming routine prac-
tice and brightening the outlook for people with cancer
globally [4]. Across all cancers, long-term patient survival
now exceeds 50% in many developed countries [5].
But progress like this brings its own challenges. The dra-
matic expansion of therapeutic options and the rise of preci-
sion oncology have made clinical decision making far more
complex than ever before. Although oncologists are guided
by a number of best practice recommendations underpinned
by formal research, they face the everyday challenge of inter-
preting and implementing these guidelines within the diverse
and heterogenous real world, where individual patient char-
acteristics often do not match those in defined clinical trial
populations. Inevitably, day-to-day clinical decisions are
influenced by personal experience and that of close con-
tacts or an immediate peer group—sometimes on the basis
of very small numbers of patients within a particular dis-
ease subtype. This, in turn, has given rise to notable varia-
tions in practice, with implications for quality of care [6, 7].
Such variations are also driven by differing national cancer
care programs, which have evolved through localized
perspectives.
Meanwhile, the number of patients with a diagnosis of
cancer is rising inexorably. A 10% increase in cancer incidence
is expected over the next 15 years in Europe [8], and greater
cancer survival beyond primary treatment means patients are
often living long enough to require further interventions down
the line. Furthermore, innovation is expensive; increasing pres-
sure on health care budgets is challenging financial sustainabil-
ity, which in turn may limit patient access to the treatments
most likely to benefit them [9, 10].
Urgent questions need to be answered. How can oncolo-
gists ensure they are using the novel and costly treatments
now at their disposal in the most optimal way? How can they
address variations in practice? How can they identify the
best treatment approaches for particular biomarker-defined
subgroups? How can they efficiently identify new priorities
for clinical research in an increasingly crowded research
arena? How can they balance the desire to sustain innova-
tion with the need to deliver better value cancer care?
Vital clues to how to answer these questions can be found
within real-world data (i.e., the huge volume of data on the
day-to-day use of cancer medicines residing in sources outside
of formal clinical trials). The untapped potential of real-world
data has long been recognized [11, 12], but practical hurdles
to efficient data capture and concerns about issues like valid-
ity, comparability, bias, and data protection have stood in the
way [13, 14]. Although daunting, these challenges are not
insurmountable. The solution must lie in collaborative data
sharing, supported by technological innovation.
A range of real-world data initiatives are already under
way. These include cancer registries that typically focus on
specific malignancies. Although registry capabilities are evolv-
ing, many are still focused on elucidating epidemiology [15],
and, although they play a valuable role, they are not set up to
generate insights across the board at speed. Other initiatives
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take a broader focus but depend on manpower for data
extraction, data analysis, or both [16]. The geographical scope
varies and some notable ventures are U.S. centric [17–19].
Many have time-limited funding. Many require sites to modify
or adapt their current information technology systems and
infrastructures. Significantly, there is almost always a time lag
between data capture and the availability of validated, aggre-
gated analyses [16].
However, technology has now advanced to the point at
which data from diverse and fragmented clinical systems can
be collated without the need for manual intervention and can
be validated, rendered nonidentified, aggregated, translated
into a “common language,” and analyzed in close to real time.
This opens the door to a major new opportunity: an opportu-
nity for true collective learning. By coming together from
across Europe to share data on daily clinical decision making
within a robust and centralized framework, a mechanism is
created that enables the clinical community to keep on top of
the vast amount of change and to access, at speed, potentially
practice-changing insights from an immeasurably greater net-
work than their own personal peer groups. The Oncology Data
Network (ODN) has been established to deliver the practical
reality of this vision. It is a fully cooperative, collaborative
data-sharing European network providing near real-time infor-
mation on cancer medicine usage at scale.
THE ODN CAPTURES BIG DATA TO MEET THE CHALLENGES
OF PRECISION CANCER MEDICINE
Creation of the ODN was supported by the Collaboration for
Oncology Data in Europe, a multistakeholder, multidisciplinary
initiative that was established in 2017 by human data science
company IQVIA (Durham, NC; formerly QuintilesIMS), with
the backing of leading biopharmaceutical companies. The key
features of the ODN are summarized in Table 1. Data on can-
cer medicine use are collated through technology-enabled
automation direct from participating hospitals’ existing sys-
tems. A “common data model” translates data from diverse
sources into a common language enabling direct comparabil-
ity via an automated regimen mapping algorithm.
A data-sharing platform of the size, scale, and ambition of
the ODN could deliver a wide range of clinically relevant bene-
fits: (a) insights from ODN analyses may enable clinicians to
reflect on their current practice at a “big picture” level; com-
pare their own clinical decision making with that of their
peers in privacy-protecting ways locally, regionally, nationally,
and internationally; carry out assessments comparing real-
world treatment regimens with those recommended by best
practice guidelines; and benchmark clinical endpoints against
other institutions to drive up quality. (b) The network may
offer an agile way for participating sites to connect and set up
new collaborations, both at scale and within special interest
subgroups (e.g., groups focused on specific tumors or geno-
types). (c) ODN analyses could help inform policy making
within oncology by providing regulators with clinical context
for new drug candidates and insights on real-world use of
postapproval products. In addition to using data from ran-
domized controlled trials, decision-makers are increasingly val-
uing robust, dependable real-world data analyses when
considering the role and value of particular treatments and
when formulating clinical guidelines [20, 21]. (d) The ODN
has the potential to stimulate and catalyze research in
numerous ways. For example, it could be used to shed light
on parameters such as the case mix, speed of adoption and
performance of novel medicines, and the anecdotal use of
therapies in rare tumor types and defined subgroups. It could
Table 1. Features of the ODN
Scale Any oncology treatment center in Europe
may join the Oncology Data Network (ODN)
free of charge and may contribute data for
any patient and any cancer type
Built for the long term, the ODN dataset is
amenable to expansion and responsive to
emergent needs
Speed Validated, aggregated analyses are made
available to contributors in near real time,
ensuring they reflect current practice
Contributors are able to access a suite of
versatile, intuitive tools allowing in-depth
exploration of their own practice, benchmarking
against others, tracking over time, and an ability
to store and repeat analytics
Comparability Irrespective of its source or configuration, the
ODN accepts data capture in ways that make
sense to each center, then translates the data
in auditable ways into a common language
(common data model) to allow comparability
across the community of practice
The ODN maintains comprehensive central
catalogs (e.g. of cancer types and treatment
regimens) to ensure that reference data are
kept up to date based on emerging practice
and evidence
Security The ODN is fundamentally committed to
protecting the privacy of individual patients
and healthcare professionals. Fully aligned
with both General Data Protection Regulation
and national regulations, the architecture of
the platform was built following the principles
of “data protection by design”
All contributed data are rendered nonidentified
through a validated multistage process
The ODN platform has undergone extensive
security checks to safeguard data from
unauthorized access and has been tested and
certified by an independent industry-
accredited security company
Efficiency Technology-enabled collation of information
direct from clinical systems—and automated
daily transmission to an independent
approved data center—ensures seamless
integration and minimum disruption to
existing hospital processes
Joining the ODN may ultimately reduce the
burden of manual data entry onto different
platforms within individual sites and may
help sites improve data quality
Integrity Robust, transparent governance by expert
committees at both European and country
levels guides the conduct of the initiative both
scientifically and ethically and ensures outputs
are of optimal value centrally and locally
Defined processes are in place for making
outputs available to the entire oncology
community and to ensure insights are never
deployed for marketing, promotional, or
insurance purposes, but always in the
interests of patient care.
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enable observational-type studies to be carried out quickly
and cost-effectively. It could also facilitate recruitment for
clinical trials by identifying sites that have potentially eligible
patients. (e) Finally, ODN insights on the real-world use and
benefits of cancer medicines may enable flexible, value-
based payment agreements to be put in place, which will
help to safeguard long-term financial sustainability without
disincentivizing innovation.
ODN PROGRESS TO DATE
The ODN’s long-term vision is highly ambitious. To realize
this ambition, a pragmatic, focused approach to building
the network has been taken:
Geographic reach: the ODN has been initially established
across more than seven countries (including Austria, Belgium,
England, France, Germany, The Netherlands, and Spain). The
intention was to start in a focused way to maximize the
chances of success, but the ultimate objective is to expand
across Europe.
Data set: a concise initial data set, focusing on the key
parameters that describe cancer medicine use, has been
defined (Table 2). However, this is likely to expand and evo-
lve once the backbone of the platform has been established.
In addition, the value of the data fields summarized in Table 2
is being extended through a collaboration with the European
CanCer Organisation, which has identified “pragmatic” out-
come metrics in cancer care that can be measured at scale in
routine clinical care. These include parameters such as dura-
tion of therapy and early discontinuation.
As of July 2019, 119 cancer centers have joined the ODN,
representing approximately 83,000 patients receiving active
cancer medical treatment. The infrastructure is in place, pro-
spective data are being collated, and analyses have been suc-
cessfully generated in close to real time. Participating sites
are already benefiting from the ability to interrogate their
own data, and comparative analyses across centers and coun-
tries are expected to be available toward the end of 2019.
CONCLUSION: A CALL TO COLLABORATE
Only by pooling their routine clinical experiences can oncolo-
gists generate the statistical power to validate specific
therapeutic approaches within each of the distinct and rare
conditions they treat [22]. In a recent white paper, the
European Organisation for Research and Treatment of Cancer
and the BioMed Alliance called for “an integrated pan-
European infrastructure to support the use of patient data for
health research” [23]. There is also strong global interest in
the concept of a “learning health care system” in which
knowledge accumulates as a direct byproduct of ongoing
patient care [19].
The ODN offers Europe’s cancer centers the opportunity
to collaboratively fill the information gap that is preventing
full optimization of routine cancer care—and to collectively
benefit from the outputs. By revealing how cancer medicines
are actually used in daily practice across Europe, ODN
insights will help demonstrate the benefit that innovative
treatments bring to patients in the real world while broad-
ening the opportunity for individual patients to receive
the therapies most likely to benefit them. Once mature,
the size, reach, and statistical power of the ODN should
provide the most inclusive and extensive picture of real-
world cancer care across Europe to date—and every cen-
ter that joins helps the network to grow, increasing its
impact for all members and ultimately for the wider oncol-
ogy community.
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